Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes

被引:66
作者
Su, LD
Lowe, L
Bradford, CR
Yahanda, AI
Johnson, TM
Sondak, VK
机构
[1] Univ Michigan, Ctr Comprehens Canc, Dept Pathol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Ctr Comprehens Canc, Dept Dermatol, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Ctr Comprehens Canc, Dept Otorhinolaryngol, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Ctr Comprehens Canc, Dept Surg, Div Surg Oncol, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Ctr Comprehens Canc, Dept Surg, Div Plast Surg, Ann Arbor, MI 48109 USA
关键词
D O I
10.1067/mjd.2002.119563
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Sentinel lymph node biopsy (SLNBx) can identify Merkel cell carcinoma (MCC) micrometastasis. Objective: We attempted to examine the effectiveness of immunostaining and identify antibodies most appropriate for evaluation of SLNBxs for MCC. Methods. Histopathologic material from 10 patients with MCC who had SLNBx was reviewed. Results: Twenty-three SLNBxs from 10 patients appeared tumor-free in routine hematoxylin-eosin (H&E)-stained sections. However, tumor cells were detected in immunostained sections from 5 (2216) of 23 SLNBxs in 4 (40%) of 10 patients. Immunostains with pancytokeratin (panCK), cytokeratin-20 (CK-20), neurofilament protein, and chromogranin A were used for all primary and SLNBx specimens. All 5 (100%) micrometastatic foci stained strongly for CK-20 and panCK. Background normal lymph node tissue also stained for panCK but not for CK-20. Conclusion: Examination of H&E sections alone is insufficient for excluding micrometastatic MCC in sentinel lymph nodes, We observed the greatest sensitivity and specificity with anti-CK-20 antibody in identifying micrometastatic MCC in sentinel lymph nodes.
引用
收藏
页码:661 / 666
页数:6
相关论文
共 37 条
[1]   Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma [J].
Albertini, JJ ;
Cruse, CW ;
Rapaport, D ;
Wells, K ;
Ross, M ;
DeConti, R ;
Berman, CG ;
Jared, K ;
Messina, J ;
Lyman, G ;
Glass, F ;
Fenske, N ;
Reintgen, DS .
ANNALS OF SURGERY, 1996, 223 (02) :217-224
[2]  
Alex J C, 1996, Surg Oncol Clin N Am, V5, P33
[3]   Surgical management of Merkel cell carcinoma [J].
Allen, PJ ;
Zhang, ZF ;
Colt, DC .
ANNALS OF SURGERY, 1999, 229 (01) :97-105
[4]  
Ames SE, 1998, J SURG ONCOL, V67, P251, DOI 10.1002/(SICI)1096-9098(199804)67:4<251::AID-JSO8>3.0.CO
[5]  
2-7
[6]   Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients [J].
Bostick, PJ ;
Chatterjee, S ;
Chi, DD ;
Huynh, KT ;
Giuliano, AE ;
Cote, R ;
Hoon, DSB .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2632-2640
[7]  
CABANAS RM, 1977, CANCER, V39, P456, DOI 10.1002/1097-0142(197702)39:2<456::AID-CNCR2820390214>3.0.CO
[8]  
2-I
[9]   Cytokeratin 20 immunoreactivity distinguishes merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites [J].
Chan, JKC ;
Suster, S ;
Wenig, BM ;
Tsang, WYW ;
Chan, JBK ;
Lau, ALW .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1997, 21 (02) :226-234
[10]  
De Cicco C, 2000, BRIT J CANCER, V82, P295